Skip to main content
EJNMMI Research
Fig. 3 | EJNMMI Research

Fig. 3

From: Early 18F-FDG uptake as a reliable imaging biomarker of T790M-mediated resistance but not MET amplification in non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors

Fig. 3

Long-term tumor growth of NSCLC xenografts in untreated and treated animals. Tumor growth of a H1975 and b H1993 xenografts in animals treated with 100 mg/kg of erlotinib, WZ4002, crizotinib, or vehicle. Data are expressed as a percentage of tumor volume at day 1 considered as 100 %. At each time point, significant differences versus vehicle-treated animals were indicated with *p < 0.05 and **p < 0.01 whereas the symbol # indicated significant differences versus erlotinib-treated animals, p < 0.05

Back to article page